Collagen News and Research

Latest Collagen News and Research

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

Valensa International (Eustis, FL USA) announced today that it has entered into a license agreement with Biova, LLC (Johnston, Iowa USA) that will allow Valensa to include the patented BiovaFlex(TM) water-soluble egg shell membrane ingredient in a proprietary new series of formulated joint health products.

19 Feb 2010

HealthTrust Purchasing Group signs 3-year vascular graft procurement contract with MAQUET Cardiovascular

MAQUET Cardiovascular, LLC, a leading provider of cardiovascular technologies, announced today that it has signed a three year contract with HealthTrust Purchasing Group, LP to provide woven and knitted textile vascular grafts to the HealthTrust membership. The contract includes the HEMASHIELD product line and other vascular grafts, which are used to surgically repair or replace damaged blood vessels, including the aorta.

18 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Glissandra Skincare™ Inc., dedicated to the research, development, and manufacturing of anti-aging skincare products, announced it has signed its first distributorship agreement granting Enchanted Meadow the rights to distribute Glissandra to its more than 2000 spa and gift industry retailers throughout the US and Canada.

10 Feb 2010

Cynosure settles patent infringement lawsuit against CoolTouch

Cynosure, Inc., developer of the award-winning Smartlipo™ LaserBodySculpting(SM) procedure for minimally invasive removal of fat, and its largest shareholder, El.En. S.p.A, today announced a settlement of their patent infringement lawsuit against CoolTouch, Inc. Cynosure and El.En. alleged that CoolTouch's 1320 nm CoolLipo™ laser system infringed on El.En.'s U.S. Patent No. 6,206,873 (the 873 patent) licensed to Cynosure, which covers laser technology to remove subcutaneous fat.

9 Feb 2010

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.

9 Feb 2010

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

REGENERX BIOPHARMACEUTICALS, INC. announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tβ4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice.

6 Feb 2010

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration (FDA) has approved Xiaflex, a new drug to treat Dupuytren's contracture (or disease) that was discovered and developed by Marie A. Badalamente, Ph.D., and Lawrence C. Hurst, M.D., in the Department of Orthopaedics at Stony Brook University Medical Center.

4 Feb 2010

BioSpecifics Technologies' XIAFLEX receives FDA approval

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that the U.S. Food and Drug Administration (FDA) has approved XIAFLEX™, a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.

3 Feb 2010

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients.

3 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

VHGI sells Secure eHealth to WNDM

VirtualHealth Technologies, Inc. announced today that it has completed the sale of secure data and messaging provider, Secure eHealth, LLC, along with certain other technology assets to Wound Management Technologies, Inc. as previously announced in the January 11 press release. In addition to the sale of Secure eHealth, VHGI has also transferred all of the intellectual property assets of the real-time prescription drug monitoring business conducted by its subsidiary, VPS Holdings, LLC to Wound Management.

2 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

Salient Surgical Technologies of Portsmouth, New Hampshire, has partnered with Exeter Hospital in Exeter, New Hampshire and Moffitt Cancer Center in Tampa, Florida, to donate equipment and supplies for a mission to aid victims of the January 12 earthquake in Haiti.

30 Jan 2010

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

RTI Biologics Inc. (RTI), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB).

29 Jan 2010

Aubrey receives FDA clearance to market bioengineered wound dressings in U.S.

Aubrey Inc., an advanced wound care company, announced it has received clearance from the US Food and Drug Administration (FDA) to market the AWBAT Plus product line in the United States.

28 Jan 2010

Kensey Nash announces financial results for second quarter of fiscal year 2010

Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.

28 Jan 2010

Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010

Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.

27 Jan 2010

Scientific/technical review for XIAFLEX' European MAA commences

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.

21 Jan 2010

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Pfizer Inc. and Auxilium Pharmaceuticals, Inc. today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the validation phase successfully. As a result, the scientific/technical review procedure commenced on 21 January 2010.

21 Jan 2010

Collagen News and Research

Latest Collagen News and Research

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

HealthTrust Purchasing Group signs 3-year vascular graft procurement contract with MAQUET Cardiovascular

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Cynosure settles patent infringement lawsuit against CoolTouch

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

BioSpecifics Technologies' XIAFLEX receives FDA approval

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

VHGI sells Secure eHealth to WNDM

Researchers design bioactive nanomaterial that promotes cartilage growth

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

Aubrey receives FDA clearance to market bioengineered wound dressings in U.S.

Kensey Nash announces financial results for second quarter of fiscal year 2010

Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010

Scientific/technical review for XIAFLEX' European MAA commences

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Collagen News and Research

Latest Collagen News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in